BNB PLUS CORP. Income Taxes Disclosure
NOTE I – INCOME TAXES
The income tax provision (benefit) for the fiscal years ended September 30, 2025 and 2024 consists of the following:
| 2025 | | 2024 | |||
Federal: | ||||||
Current | $ | — |
| $ | — | |
Deferred |
| (2,198,000) |
| 5,874,000 | ||
| (2,198,000) |
| 5,874,000 | |||
State and local: |
|
|
| |||
Current |
| — |
| — | ||
Deferred |
| (133,115) |
| 417,000 | ||
| (133,115) |
| 417,000 | |||
Foreign: |
| |||||
Current | — | — | ||||
Deferred | (724,000) | (11,000) | ||||
| (724,000) |
| (11,000) | |||
Change in valuation allowance |
| (2,371,000) |
| (6,280,000) | ||
|
|
| ||||
Income tax provision (benefit) | $ | (684,115) |
| $ | — | |
The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. statutory rate to losses before income tax expense for the years ended September 30, 2025 and 2024 as follows:
| 2025 | | 2024 |
| |
Statutory federal income tax rate |
| 21.00 | % | 21.00 | % |
Statutory state and local income tax rate (1%, as of September 30, 2025 and 2024), net of federal benefit |
| 2.77 | % | 10.19 | % |
Stock based compensation |
| (3.98) | % | 2.04 | % |
Permanent differences related to warrants | 0.42 | % | 20.33 | % | |
Other permanent differences |
| 0.19 | % | (2.49) | % |
Federal R&D Credit | 1.03 | % | (2.43) | % | |
Adjustment for prior year’s NOLs | (1.04) | % | (137.65) | % | |
Change in deferred tax rate |
| (1.18) | % | (0.81) | % |
Change in valuation allowance |
| (14.91) | % | 89.82 | % |
Effective tax rate |
| 4.30 | % | 0.00 | % |
NOTE I – INCOME TAXES, continued
Deferred income taxes result from temporary differences in the recognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset and liabilities result principally from the following:
| 2025 | | 2024 | |||
Deferred tax assets (liabilities): |
| |
| | ||
Net operating loss carryforward | 21,340,000 | 18,463,000 | ||||
Stock-based compensation |
| 499,000 |
| 1,309,000 | ||
Depreciation and amortization |
| 149,000 |
| 333,000 | ||
Impairment of Intangibles | 241,000 | 222,000 | ||||
Other | 91,000 | 141,000 | ||||
Capitalized Research and Development | 1,726,000 | 1,386,000 | ||||
Lease Liability |
| 49,000 |
| 200,000 | ||
Tax credits |
| 3,064,000 |
| 2,885,000 | ||
Deferred tax assets | 27,159,000 | 24,939,000 | ||||
Intellectual Property | — | (684,000) | ||||
ROU Asset | (49,000) | (200,000) | ||||
Deferred tax (liability) | (49,000) | (884,000) | ||||
Less: Valuation allowance |
| (27,110,000) |
| (24,739,000) | ||
Net Deferred Tax Asset / (Liability) | — | (684,000) | ||||
As of September 30, 2025, the Company has approximately $83,393,000 of Federal and $55,226,000 of State net operating loss “NOL” carryforwards available. Pursuant to Internal Revenue Code Section 382, the Company’s ability to utilize the NOLs is subject to certain limitations due to changes in stock ownership. The annual limitation ranges between $44,000 and $2,380,000 and any unused amounts can be carried forward to subsequent years. The Federal NOLs generated in tax years beginning after 12/31/2017 have no expiration period due to the Tax Cuts and Jobs Act that was enacted in March 2020.
The Company has provided a full valuation allowance against all of the net deferred tax assets based on management’s determination that it is more likely than not that the net deferred tax assets will not be realized in the future. The valuation allowance increased by $2,371,000.
The Company has Federal research and development credits of approximately 2,533,000 that will expire after 2034. The Company also has state investment tax credits of $485,000 that will expire after 2029.
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (“OBBBA”). The OBBBA makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. ASC 740, “Income Taxes”, requires the tax effects of changes in tax rates and tax law be recognized in the period in which the legislation is enacted. The Company completed its initial assessment of OBBBA and there was no material impact to the Company’s effective tax rate for the fiscal year ended September 30, 2025. The Company will continue to evaluate the impact of the new legislation on its consolidated financial statements as additional guidance is issued.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Dec 22, 2025 | Showing above |
| 2024 | Dec 17, 2024 | |
| 2023 | Dec 7, 2023 | |
| 2022 | Dec 14, 2022 | |
| 2021 | Dec 9, 2021 | |
| 2020 | Dec 17, 2020 | |
| 2019 | Dec 12, 2019 | |
| 2018 | Dec 18, 2018 | |
| 2017 | Dec 28, 2017 | |
| 2016 | Dec 6, 2016 | |
| 2015 | Dec 14, 2015 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.